ABSTRACT
AIMS: In healthy individuals, intragastric administration of the branched-chain amino acids, leucine and isoleucine, diminishes the glycaemic response to a mixed-nutrient drink, apparently by stimulating insulin and slowing gastric emptying, respectively. This study aimed to evaluate the effects of leucine and isoleucine on postprandial glycaemia and gastric emptying in type-2 diabetes mellitus (T2D). METHODS: 14 males with T2D received, on 3 separate occasions, in double-blind, randomised fashion, either 10 g leucine, 10 g isoleucine or control, intragastrically 30 min before a mixed-nutrient drink (500 kcal; 74 g carbohydrates, 18 g protein, 15 g fat). Plasma glucose, insulin and glucagon were measured from 30 min pre- until 120 min post-drink. Gastric emptying of the drink was also measured. RESULTS: Leucine and isoleucine stimulated insulin, both before and after the drink (all P < 0.05; peak (mU/L): control: 70 ± 15; leucine: 88 ± 17; isoleucine: 74 ± 15). Isoleucine stimulated (P < 0.05), and leucine tended to stimulate (P = 0.078), glucagon before the drink, and isoleucine stimulated glucagon post-drink (P = 0.031; peak (pg/mL): control: 62 ± 5; leucine: 70 ± 9; isoleucine: 69 ± 6). Neither amino acid affected gastric emptying or plasma glucose (peak (mmol/L): control: 12.0 ± 0.5; leucine: 12.5 ± 0.7; isoleucine: 12.0 ± 0.6). CONCLUSIONS: In contrast to health, in T2D, leucine and isoleucine, administered intragastrically in a dose of 10 g, do not lower the glycaemic response to a mixed-nutrient drink. This finding argues against a role for 'preloads' of either leucine or isoleucine in the management of T2D.
Subject(s)
Amino Acids, Branched-Chain/therapeutic use , Blood Glucose/drug effects , Diabetes Mellitus, Type 2/blood , Gastric Emptying/drug effects , Isoleucine/therapeutic use , Leucine/therapeutic use , Postprandial Period/drug effects , Adult , Aged , Amino Acids, Branched-Chain/pharmacology , Cross-Over Studies , Dietary Supplements , Double-Blind Method , Energy Drinks , Humans , Isoleucine/pharmacology , Leucine/pharmacology , Male , Middle AgedABSTRACT
There is evidence that alpha-lipoic acid (ALA) supplementation plays an important role in preventing cardiovascular diseases. However, its effect, specifically, on endothelial function (EF) is unclear. Therefore, this systematic review and meta-analysis aimed to evaluate the effects of ALA supplementation on EF. Databases including PubMed/Medline, Scopus, and ISI Web of Science were searched to identify eligible publications from inception up to April 2020. Randomized controlled trials assessing the effect of ALA supplementation on flow-mediated dilation (FMD) levels in adults were included. The pooled results were obtained using the random-effects model and are expressed as weighted mean differences (WMD) with 95% confidence intervals (CI). Five studies including six effect sizes and 300 participants were included. ALA supplementation significantly increased FMD levels by 2.36% (95% CI: 1.21-3.51; p < .001), compared with the control. Subgroup analyses suggested that the effects of ALA on FMD could be changed by age and health status of the participants. Dose-response analysis also showed that ALA dosage had a significant non-linear effect on FMD levels. The results showed that ALA supplementation appears to improve the EF. However, the role of ALA supplementation in improving other biomarkers of EF requires further research.
ABSTRACT
BACKGROUND: Oxidative stress plays an important role in the occurrence of chronic diseases. Zinc supplementation is also known to be an antioxidant agent. While, there is no review on the effects of zinc supplementation on oxidative stress, this study aimed to systematically summarize randomized clinical trials (RCTs) which have evaluated the impacts of zinc supplementation on oxidative stress biomarkers. METHODS: Systematic searches were performed using the PubMed/Medline, Scopus, and Google Scholar databases, up to April 2020. All RCTs assessed the effect of oral zinc supplementation on serum malondialdehyde (MDA), total antioxidant capacity (TAC), glutathione (GSH), and nitric oxide (NO) levels, were included. For each variable, mean differences (MD) and standard deviations (SDs) were combined using the random-effects model, and the fractional polynomial model was used to implement the dose-response analysis. RESULTS: Ten RCTs were included. The pooled analysis of data showed that zinc supplementation significantly reduced MDA levels (MD: -0.42 µmol/L; 95 % CI: -0.71 to -0.13), increased serum TAC (MD: 225.96 mmol/L; 95 % CI: 68.42-383.5) and GSH levels (MD: 49.99 µmol/L; 95 % CI: 2.25 t 97.73), compared with the placebo group. In contrast, no significant changes were seen in NO levels following zinc supplementation (MD: -1.66 µmol/L; 95 % CI: -5.89 to 2.57). Dose-response analysis showed a significant non-linear relationship between zinc supplementation dosage and serum levels of MDA (p < 0.01), but not other biomarkers. CONCLUSIONS: The current study showed that zinc supplementation would significantly decrease MDA and increase TAC and GSH, but not NO levels. Thus, it encourages the use of zinc supplementation in oxidative stress-related diseases.
Subject(s)
Antioxidants/therapeutic use , Dietary Supplements , Oxidative Stress/drug effects , Zinc Compounds/therapeutic use , Adult , Aged , Antioxidants/adverse effects , Biomarkers/blood , Dietary Supplements/adverse effects , Female , Glutathione/blood , Humans , Male , Malondialdehyde/blood , Middle Aged , Nitric Oxide/blood , Randomized Controlled Trials as Topic , Time Factors , Treatment Outcome , Young Adult , Zinc Compounds/adverse effectsABSTRACT
Background & Objectives: Despite controversies, no earlier study has systematically summarized findings from earlier studies on the effect of cinnamon supplementation on blood pressure. Therefore, current systematic review and meta-analysis was done on the effect of cinnamon supplementation on systolic blood pressure (SBP) and diastolic blood pressure (DBP) in adults.Methods: Relevant studies published up to July 2019 were searched through PubMed/Medline, Scopus, ISI Web of Science, Embase and Google Scholar. All randomized clinical trials investigating the impact of oral cinnamon supplementation on any of the blood pressure parameters including SBP or/and DBP were included.Results: Out of 469 citations, 9 trials that enrolled 641 subjects were included. Cinnamon supplementation resulted in significant reduction in SBP (Weighted Mean Differences (WMD): -6.23 mmHg, 95% CI: -10.69 to -1.77, P = 0.006) and DBP (WMD: -3.93 mmHg, 95% CI: -6.33 to -1.52, P = 0.001). Greater effects on SBP were detected in trials using ≤2 g cinnamon, lasted ≥12 weeks and participants aged <50 years' old. DBP was also reduced by using lower doses. However, no significant non-linear associations were found between cinnamon supplementation dosage and study duration with both SBP (For dosage: Pnon-linearity = 0.35, for duration: Pnon-linearity = 0.21) and DBP (For dosage: Pnon-linearity = 0.27, for duration: Pnon-linearity = 0.41).Conclusions: We found a significant reduction in both SBP and DBP following cinnamon supplementation in adults. It could be proposed as a hypotensive supplement in hypertension management.
Subject(s)
Antihypertensive Agents , Cinnamomum zeylanicum , Dietary Supplements , Hypertension , Adult , Antihypertensive Agents/pharmacology , Blood Pressure , Humans , Hypertension/drug therapy , Randomized Controlled Trials as TopicABSTRACT
BACKGROUND: Quercetin, which is considered as a health-promoting antioxidant, belongs to the broad flavonoids group. Numerous experimental studies have proved that quercetin and vitamin C provide anti-inflammatory and antioxidant properties. The aim of this study is to assess the effects of both quercetin and vitamin C on lipid profile and muscle damage in human subjects. METHODS: A randomized, placebo-controlled, double-blind clinical trial was carried out on 60 males for eight weeks. The subjects were randomly assigned to one of the four groups: 1) quercetin + vitamin C (500 mg/day quercetin + 200 mg/day vitamin C) 2) quercetin (500 mg/day quercetin + 200 mg/day placebo) 3) vitamin C (500 mg/day vitamin C + 200 mg/day placebo) and 4) placebo (500 mg/day placebo + 200 mg/day placebo). Blood samples, body weight and percent of body fat were measured before and after intervention. In addition, dietary intake was estimated using 24-h recall. RESULTS: No significant changes occurred in high-density lipoprotein levels between groups and in the four groups before and after supplementation. Low density lipoprotein values decreased significantly (P = 0.048) in the "Quercetin + Vit C" group but decrease was not considerable in other groups before and after intervention and among groups. Fat-soluble vitamins' intake was significantly high among 4 groups. CONCLUSIONS: Quercetin and vitamin C supplementation may not be beneficial in lipid profile improvement, although it may reduce induce muscle damage and body fat percent.